ROBAX PLATINUM TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

IBUPROFEN; METHOCARBAMOL

Beschikbaar vanaf:

GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC

ATC-code:

M03BA53

INN (Algemene Internationale Benaming):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dosering:

200MG; 500MG

farmaceutische vorm:

TABLET

Samenstelling:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Toedieningsweg:

ORAL

Eenheden in pakket:

18/24/40/50/60

Prescription-type:

OTC

Therapeutisch gebied:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Product samenvatting:

Active ingredient group (AIG) number: 0248961001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2003-04-02

Productkenmerken

_GlaxoSmithKline Consumer Healthcare Inc. _
_Page 1 of 36_
PRODUCT MONOGRAPH
ROBAX PLATINUM
Methocarbamol and Ibuprofen Caplets
500 mg/200 mg
Muscle Relaxant/Analgesic
GlaxoSmithKline Consumer Healthcare Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Preparation:
Dec 16, 2003
Date of Revision:
April 3, 2020
Submission Control No: 236559
_ _
_GlaxoSmithKline Consumer Healthcare Inc. _
_Page 2 of 36_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................20
PART II: SCIENTIFIC INFORMATION
...............................................................................21
PHARMACEUTICAL INFORMATION
..........................................................................21
CLINICAL TRIALS
..........................................................................